Medicure Inc. (FRA:NGQ1)

Market Cap	9.48M +40.4%
Revenue (ttm)	19.77M +38.3%
Net Income	-4.59M
EPS	-0.44
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.8900
Previous Close	0.7850
Day's Range	0.8900 - 0.8900
52-Week Range	0.5450 - 0.8900
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 23, 2026

About Medicure

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological i...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 38
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NGQ1

Financial Performance

In 2025, Medicure's revenue was 28.86 million, an increase of 31.72% compared to the previous year's 21.91 million. Losses were -7.10 million, 583.1% more than in 2024.

Financial numbers in CAD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error